Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11961364 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL6133472 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL11961363 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL8588353 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL10591424 | 0.81 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL10591418 | 0.81 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL5881237 | 0.81 | IDO1 (0.44) | SLC6A4OGA | |
| SCHEMBL11961360 | 0.80 | TMEM97 (0.38) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL1487127 | 0.80 | TMEM97 (0.38) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL11961357 | 0.80 | TMEM97 (0.38) | SLC6A2SLC6A4SLC6A3HTTOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3255991-B1 | PICOLINAMIDES AS FUNGICIDES | DOW AGROSCIENCES LLC (US) | 2020-09-30 | — | — | EP | disclosed |
| US-8530452-B2 | Tricyclic boron compounds for antimicrobial therapy | MICURX PHARMACEUTICALS, INC. (KY) | 2013-09-10 | — | — | US | disclosed |
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | MICURX PHARMACEUTICALS, INC. (KY) | 2013-06-27 | — | — | US | disclosed |
| CN-1291979-C | Imidazole compounds and their use as adenosine deaminase inhibitors | JUJISAWA PHARAMCEUTICAL CO LTD (JP) | 2006-12-27 | — | — | CN | disclosed |
| CN-1319095-A | Imidazole compounds and their use as adenosine deaminase inhibitors | JUJISAWA PHARAMCEUTICAL CO LTD (JP) | 2001-10-24 | — | — | CN | disclosed |
| EP-1098885-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000005217-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | TBCA, TBCB, BTD | SLC6A2 507/4885SLC6A4 1958/4885SLC6A3 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.